Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Flortaucipir (AV1451)

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Tau
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

The tracer picked out AD cases with a sensitivity and specificity of around 90 percent. At the dementia stage of disease, the marker outperformed both amyloid imaging and structural MRI. However, flortaucipir missed cases at the prodromal stage, when tau pathology is sparse.

What is Required from Patients

injection of radioactive tracers, mild discomfort, x-ray, blood draw in clinic visit

What is Required from the Health System

PET technician, PET scanner, dyes, x-ray, phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

University of Pennsylvania; University of California, Berkeley; Lawrence Berkeley National Laboratory;University of Michigan, Ann Arbor; Avid Radiopharmaceuticals, Inc.; Banner Alzheimer's Institute;Butler Hospital, Providence; Neuropsychiatric Research Center of Southwest Florida; Molecular Neuroimaging Inc., New Haven ; Lund University; VU University Medical Center; University of California San Francisco; Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; University of Gothenburg; Skåne University Hospital; Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul

  1. “Flortaucipir Imaging Distinguishes Alzheimer’s From Other Disorders.” Alzforum. https://www.alzforum.org/news/research-news/flortaucipir-imaging-distinguishes-alzheimers-other-disorders

  2. Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., ... & Jagust, W. J. (2015). Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. Journal of Nuclear Medicine, 56(4), 567-574. https://www.ncbi.nlm.nih.gov/pubmed/25745095

  3. Nasrallah, I. M., Chen, Y. J., Hsieh, M. K., Phillips, J. S., Ternes, K., Stockbower, G. E., ... & Wolk, D. A. (2018). 18F-Flortaucipir PET/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease. Journal of Nuclear Medicine, 59(2), 299-306. https://www.ncbi.nlm.nih.gov/pubmed/28747523

  4. Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., ... & Ohlsson, T. (2018). Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. Jama, 320(11), 1151-1162. https://www.ncbi.nlm.nih.gov/pubmed/30326496

  5. Pontecorvo, M. J., Devous Sr, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., ... & Xiong, H. (2017). Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain, 140(3), 748-763. https://www.ncbi.nlm.nih.gov/pubmed/28077397